Skip to search formSkip to main contentSkip to account menu

PD 166326

Known as: PD166326 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyridinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
the mutation pattern for PD166326, an alternative Abl kinase inhibitor A cell-based screen for resistance of Bcr-Abl positive leukemia identifies
Abstract In Ph+ leukemia, point mutations within the Bcr-Abl kinase domain emerged as a major mechanism of resistance toward… 
2005
2005
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients… 
Review
2003
Review
2003
Advances in Brief A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K 562 Cells and Is Effective against STI 571-resistant Bcr-abl Mutants 1
Inhibition of the constitutively active Bcr-abl tyrosine kinase (TK) by STI571 has proven to be a highly effective treatment for… 
2003
2003
Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
The recent success of STI-571 (Imatinib mesylate; Gleevec) in the chronic phase of CML[2][1] is a milestone in the history of… 
2002
2002
c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as…